Liggins Institute, University of Auckland, Auckland, New Zealand.
Liggins Institute, University of Auckland, Auckland, New Zealand; Department of Paediatrics: Child and Youth Health, School of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand; Environmental-Occupational Health Sciences and Non-communicable Diseases Research Group, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand; Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
Lancet Glob Health. 2023 Mar;11 Suppl 1:S11-S12. doi: 10.1016/S2214-109X(23)00095-5.
Nutritional intervention before and throughout pregnancy might promote healthy infant weight gain; however, clinical evidence is scarce. Therefore, we examined whether preconception and antenatal supplementation would affect the body size and growth of children in the first 2 years of life.
Women were recruited from the community before conception in the UK, Singapore, and New Zealand, and randomly allocated to either the intervention (myo-inositol, probiotics, and additional micronutrients) or control group (standard micronutrient supplement) with stratification by site and ethnicity. Measurements of weight and length were obtained from 576 children at multiple timepoints in the first 2 years of life. Differences in age and sex standardised BMI at age 2 years (WHO standards) and the change in weight from birth were examined. Written informed consent was obtained from the mothers, and ethics approval was granted by local committees. The NiPPeR trial was registered with ClinicalTrials.gov (NCT02509988) on July 16, 2015 (Universal Trial Number U1111-1171-8056).
1729 women were recruited between Aug 3, 2015, and May 31, 2017. Of the women randomised, 586 had births at 24 weeks or more of gestation between April, 2016, and January, 2019. At age 2 years, adjusting for study site, infant sex, parity, maternal smoking, maternal prepregnancy BMI, and gestational age, fewer children of mothers who received the intervention had a BMI of more than the 95th percentile (22 [9%] of 239 vs 44 [18%] of 245, adjusted risk ratio 0·51, 95% CI 0·31-0·82, p=0·006). Longitudinal data revealed that the children of mothers who received the intervention had a 24% reduced risk of experiencing rapid weight gain of more than 0·67 SD in the first year of life (58 [21·9%] of 265 vs 80 [31·1%] of 257, adjusted risk ratio 0·76, 95% CI 0·58-1·00, p=0·047). Risk was likewise decreased for sustained weight gain of more than 1·34 SD in the first 2 years (19 [7·7%] of 246 vs 43 [17·1%] of 251, adjusted risk ratio 0·55, 95% CI 0·34-0·88, p=0·014).
Rapid weight gain in infancy is associated with future adverse metabolic health. The intervention supplement taken before and throughout pregnancy was associated with lower risk of rapid weight gain and high BMI at age 2 years among children. Long-term follow-up is required to assess the longevity of these benefits.
National Institute for Health Research; New Zealand Ministry of Business, Innovation and Employment; Société Des Produits Nestlé; UK Medical Research Council; Singapore National Research Foundation; National University of Singapore and the Agency of Science, Technology and Research; and Gravida.
在妊娠前和整个妊娠期间进行营养干预可能会促进婴儿健康的体重增长,但临床证据有限。因此,我们研究了孕前和产前补充是否会影响儿童在生命的头 2 年的身体大小和生长。
在英国、新加坡和新西兰,妇女在怀孕前从社区招募,随机分配到干预组(肌醇、益生菌和额外的微量营养素)或对照组(标准微量营养素补充剂),并按地点和种族进行分层。在生命的头 2 年内的多个时间点从 576 名儿童中获得体重和长度的测量值。检查了年龄和性别标准化的 2 岁时 BMI(世界卫生组织标准)和出生体重变化的差异。母亲们获得了书面知情同意,当地委员会也批准了该实验。NiPPeR 试验于 2015 年 7 月 16 日在 ClinicalTrials.gov (NCT02509988)上注册(通用试验编号 U1111-1171-8056)。
2015 年 8 月 3 日至 2017 年 5 月 31 日期间,共有 1729 名妇女被招募。在随机分配的妇女中,有 586 名在 2016 年 4 月至 2019 年 1 月期间分娩,妊娠期达到 24 周或以上。在 2 岁时,根据研究地点、婴儿性别、产次、母亲吸烟情况、母亲妊娠前 BMI 和胎龄进行调整后,接受干预的母亲的孩子中,BMI 超过第 95 百分位数的比例较低(22 [9%] 名 239 名 vs 44 [18%] 名 245 名,调整后的风险比为 0.51,95%CI 0.31-0.82,p=0.006)。纵向数据分析显示,接受干预的母亲的孩子在生命的第一年经历体重快速增长的风险降低了 24%(58 [21.9%] 名 265 名 vs 80 [31.1%] 名 257 名,调整后的风险比为 0.76,95%CI 0.58-1.00,p=0.047)。在头 2 年中体重持续增加超过 1.34 SD 的风险也同样降低(19 [7.7%] 名 246 名 vs 43 [17.1%] 名 251 名,调整后的风险比为 0.55,95%CI 0.34-0.88,p=0.014)。
婴儿期的快速体重增长与未来不良代谢健康有关。在妊娠前和整个妊娠期间服用的干预补充剂与儿童在 2 岁时体重快速增长和高 BMI 风险降低有关。需要进行长期随访以评估这些益处的持久性。
英国国家卫生研究院;新西兰商业、创新和就业部;雀巢公司;英国医学研究理事会;新加坡国家研究基金会;新加坡国立大学和新加坡科技研究局;以及 Gravida。